以色列研究表明｜自然免疫力是輝瑞公司COVID疫苗的13倍
Israeli Study: Natural Immunity Is 13x Stronger Than Pfizer COVID Shots
以色列研究表明｜自然免疫力是輝瑞公司COVID疫苗的13倍！- 準備轉變 / 2021年8月29日
A new pre-print Israeli study has found that people with natural immunity to COVID-19 could be 13 times less likely to contract the respiratory virus than those who were solely vaccinated against the disease.
一項新的印刷前的以色列研究發現，對2019冠狀病毒疾病有自然免疫力的人感染呼吸道病毒的可能性是單獨接種疫苗的人的13倍。
Conducted by researchers at Maccabi Healthcare and Tel Aviv University,the yet-to-be peer-reviewed study found that when comparing individuals previously infected with the virus and those that received two jabs of the Pfizer-BioNTech shot,those with natural infection saw greater protection against the delta variant and breakthrough infection.
這項尚未經過同行評審的研究是由馬卡比醫療保健和特拉維夫大學的研究人員進行的，研究發現，當比較先前感染過這種病毒的個體和那些接受過輝瑞生物技術注射的個體時，那些自然感染的個體對 delta 變異和突破性感染有更好的保護作用。
"SARS-CoV-2-naïve vaccinees had a 13.06-fold increased risk for breakthrough infection with the Delta variant compared to those previously infected,when the first event(infection or vaccination)occurred during January and February of 2021,"the study read."The increased risk was significant for symptomatic disease as well.When allowing the infection to occur at any time before vaccination(from March 2020 to February 2021),evidence of waning natural immunity was demonstrated,though SARS-CoV-2 naïve vaccinees had a 5.96-fold increased risk for breakthrough infection and a 7.13-fold increased risk for symptomatic disease."
該研究稱："當第一次事件(感染或接種)發生在2021年1月和2月時，接種 sars-cov-2天真疫苗的人突破性感染 Delta 變異的風險比先前感染的人增加了13.06倍"。"增加的風險對症狀性疾病也是顯著的。在接種疫苗之前的任何時候(從2020年3月至2021年2月)允許感染發生時，自然免疫力下降的證據得到了證實，儘管接種 SARS-CoV-2天真疫苗的突破性感染風險增加了5.96倍，症狀性疾病風險增加了7.13倍
The analysis also found that solely vaccinated individuals"were also at a greater risk for COVID-19-related-hospitalizations compared to those that were previously infected."
分析還發現，單獨接種疫苗的個體"與之前感染的個體相比，也面臨更大的 covid-19相關住院風險。"
The study ultimately concluded that"natural immunity confers longer lasting and stronger protection against infection,symptomatic disease and hospitalization caused by the Delta variant of SARS-CoV-2,compared to the BNT162b2 two-dose vaccine-induced immunity"and that"individuals who were both previously infected with SARS-CoV-2 and given a single dose of the vaccine gained additional protection against the Delta variant."
這項研究最終得出結論認為，"與 BNT162b2兩劑量疫苗誘導免疫相比，自然免疫提供了更持久和更強有力的保護，防止 SARS-CoV-2的 Delta 變異引起的感染、症狀性疾病和住院治療"，而且"同時感染了 SARS-CoV-2並接種了單劑量疫苗的個體獲得了針對 Delta 變異的額外保護"。
https://twitter.com/RandPaul/status/1431248576684888065?ref_src=twsrc%5Etfw
While the Israeli Health Ministry has indicated that the delta variant may be more likely to cause reinfection among recovered COVID-19 patients than previous variants,the data shows that natural immunity remains effective at offering robust protection against the virus.According to the Health Ministry,4,811 Israelis have been reinfected with coronavirus,which accounts for only 0.47 percent of the nation's total recoveries.
雖然以色列衛生部已經表明 delta 變異可能比之前的變異更有可能在已經康復的2019冠狀病毒疾病患者中引起再感染，但是數據顯示，自然免疫仍然有效地提供強有力的保護來抵禦病毒。根據以色列衛生部的數據，4811名以色列人再次感染冠狀病毒，這僅佔以色列全部康復人數的0.47%。
Israel remains one of the most vaccinated countries in the world,ranking third in doses administered per 100 people.
以色列仍然是世界上接種疫苗最多的國家之一，每100人接種疫苗的劑量排名第三。
**By Shawn Fleetwood
作者：Shawn Fleetwood
**Source
留言